Mentions
Extended reach
Total likes
Video views
AI synopsis
The collective discussions showcase enthusiasm about the new genomic classifier, with phrases like 'clinically useful,' 'accurately determines risk,' and 'guide treatment' emphasizing the perceived practical impact. Posts mention the test 'Thyroid GuidePx®,' its development, and its potential to improve prognosis assessments, demonstrating high engagement and recognition of the publication's importance.
Most discussions express support and acknowledgment of the article's significance, highlighting the usefulness of the genomic classifier.
The posts demonstrate strong interest, with many sharing details about the test, its development, and potential clinical benefits.
Comments include references to the test's application, mentions of the research process, and calls to read the publication, indicating deep involvement.
The consensus suggests that this research could meaningfully influence thyroid cancer management and diagnostics, viewed as a notable advancement.
Oliver Bathe, CEO & Founder of @QualisureDx, developed a test that determines #RecurrenceRisk for papillary #thyroidcancer (PTC), called Thyroid GuidePx®. DOI: https://t.co/6Vs4agpizD Read our article: https://t.co/aYMMW54Y9Q
We are pleased to share the publication of our study on 742 #PapillaryThyroidCancer patients. This is the basis for #ThyroidGuidePx®, our new #MolecularTest that accurately determines the risk of recurrence. Link here: https://t.co/HMlFQxOOq1 #MedTwitter #EndoTwitter #ThyCa https://t.co/GwI1rYWxvv
New Research: A clinically useful and biologically informative genomic classifier for papillary thyroid cancer: Clinical management of papillary thyroid cancer depends on estimations of prognosis. Standard care, which relies on… #Endocrinology #Endo https://t.co/2GMc0d4ZuU
Professor Oliver Bathe, CEO & Founder of @QualisureDx, along with colleagues at the University of Calgary, has developed Thyroid GuidePx® - a test to accurately predict #RecurrenceRisk of papillary #thyroidcancer. DOI: https://t.co/XOE86gQ9WF Listen: https://t.co/Ci0VrPHf21
Frontiers | A clinically useful and biologically informative genomic classifier for papillary thyroid cancer. Access the recent publication through the link below: https://t.co/qUEqENKgvR #PapillaryThyroidCancer #Endocrinology #SaveYourThyroid https://t.co/YtM6WdOqMT
A Clinically Useful and Biologically Informative Genomic Classifier for Papillary Thyroid Cancer https://t.co/R9eqxSh7b1 #bioRxiv
Decisions on treating papillary thyroid cancer depend on recurrence risk estimation. Professor Oliver Bathe and team developed the Thyroid GuidePx test, using genetic data to improve risk assessment by identifying three…
Explore how molecular tests are enhancing thyroid cancer diagnosis and personalized care, featuring insights from Dr. Oliver Bathe, CEO of Qualisure Diagnostics, on cutting-edge genomic classifiers and their impact on…
Learn about thyroid cancer and recent developments in molecular testing to improve personalized treatment. Featured expert Dr. Oliver Bathe discusses innovative diagnostic solutions and clinical challenges in thyroid…
Learn more about thyroid cancer in this playlist httpsyoutubecomplaylistlistPL5tSaOk33p79pNzI2Md7pYra2tE2xRZN0sicyNlSuaqYmN6w37W. Dr. Oliver Bathe, CEO of Qualisure Diagnostics, discusses how molecular tests help…
Learn more about thyroid cancer in this playlist. Dr. Oliver Bathe discusses innovative molecular tests that help oncologists personalize treatment, improving outcomes for patients with thyroid cancer.
Learn about thyroid cancer and the clinical significance of its subtypes in this informative video. Dr. Oliver Bathe discusses advances in molecular testing that aid in personalized treatment.
Learn more about thyroid cancer in this playlist httpsyoutubecomplaylistlistPL5tSaOk33p79pNzI2Md7pYra2tE2xRZN0sicyNlSuaqYmN6w37W. Dr. Oliver Bathe discusses innovative molecular tests that enhance cancer care by guiding…
Learn more about thyroid cancer in this playlist httpsyoutubecomplaylistlistPL5tSaOk33p79pNzI2Md7pYra2tE2xRZN0sicyNlSuaqYmN6w37W. Dr. Oliver Bathe discusses innovative molecular tests developed by Qualisure Diagnostics…
Learn about innovative molecular tests that improve thyroid cancer diagnosis and treatment, with insights from Dr. Oliver Bathe, CEO of Qualisure Diagnostics, on how technology personalizes cancer care.
RT @QualisureDx: We are pleased to share the publication of our study on 742 #PapillaryThyroidCancer patients. This is the basis for #Thyro…
Professor Oliver Bathe, CEO & Founder of @QualisureDx, along with colleagues at the University of Calgary, has developed Thyroid GuidePx® - a test to accurately predict #RecurrenceRisk of papillary #thyroidcancer. DOI: https://t.co/XOE86gQ9WF Listen: https://t.co/Ci0VrPHf21
Oliver Bathe, CEO and Founder of Qualisure Diagnostics, developed a test that determines recurrence risk for papillary thyroid cancer (PTC), called Thyroid GuidePx®. Read our article: https://t.co/bIQkJpt5iI DOI: https://t.co/AIrSK6kKHJ
RT @ResearchFeature: Oliver Bathe, CEO & Founder of @QualisureDx, developed a test that determines #RecurrenceRisk for papillary #thyroidca…
Oliver Bathe, CEO & Founder of @QualisureDx, developed a test that determines #RecurrenceRisk for papillary #thyroidcancer (PTC), called Thyroid GuidePx®. DOI: https://t.co/6Vs4agpizD Read our article: https://t.co/aYMMW54Y9Q
RT @LKarras: Frontiers | A clinically useful and biologically informative genomic classifier for papillary thyroid cancer. Access the recen…
Frontiers | A clinically useful and biologically informative genomic classifier for papillary thyroid cancer. Access the recent publication through the link below: https://t.co/qUEqENKgvR #PapillaryThyroidCancer #Endocrinology #SaveYourThyroid https://t.co/YtM6WdOqMT
A clinically useful and biologically informative genomic classifier for papillary thyroid cancer https://t.co/G930Yrc7R0 #endocrinology #thyroid #endo #PapillaryThyroidCancer #PTC
Three subtypes of #papillarythyroidcancer #podcast https://t.co/YadurY4Ees via @YouTube @QualisureDx
A tool to guide #thyroidcancer treatment https://t.co/3EySxpnljw via @YouTube @QualisureDx
Do you know these #FACTS about #papillarythyroidcancer? https://t.co/ctURhObgW0 via @YouTube @QualisureDx #cancerispersonal #moleculartesting
RT @QualisureDx: We are pleased to share the publication of our study on 742 #PapillaryThyroidCancer patients. This is the basis for #Thyro…
We are pleased to share the publication of our study on 742 #PapillaryThyroidCancer patients. This is the basis for #ThyroidGuidePx®, our new #MolecularTest that accurately determines the risk of recurrence. Link here: https://t.co/HMlFQxOOq1 #MedTwitter #EndoTwitter #ThyCa https://t.co/GwI1rYWxvv
RT @CynStre: Check out our work from @QualisureDx on #thyroidcancer #prognosis A clinically useful and biologically informative genomic cl…
Check out our work from @QualisureDx on #thyroidcancer #prognosis A clinically useful and biologically informative genomic classifier for papillary thyroid cancer https://t.co/uqXG2zsXjh
RT @FrontEndocrinol: New Research: A clinically useful and biologically informative genomic classifier for papillary thyroid cancer: Clinic…
New Research: A clinically useful and biologically informative genomic classifier for papillary thyroid cancer: Clinical management of papillary thyroid cancer depends on estimations of prognosis. Standard care, which relies on… #Endocrinology #Endo https://t.co/2GMc0d4ZuU
A Clinically Useful and Biologically Informative Genomic Classifier for Papillary Thyroid Cancer https://t.co/byIKpLUXp7
A Clinically Useful and Biologically Informative Genomic Classifier for Papillary Thyroid Cancer https://t.co/rqPz5zOeDI
A Clinically Useful and Biologically Informative Genomic Classifier for Papillary Thyroid Cancer https://t.co/R9eqxSh7b1 #bioRxiv
RF
QI
FE
R
LK
B
J
RS
LL
CM
CS
B
ML